Matthew R. Wilson

机构：Beatson West of Scotland Cancer Centre · ORCID：0000-0001-5423-3270

发表论文 69 篇 · 总被引 1254 次 · h-index 16

代表论文

• Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis (2024 · HemaSphere · 被引 26)
• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 20)
• Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper (2024 · British Journal of Haematology · 被引 10)
• Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications (2024 · Blood · 被引 7)
• Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper (2024 · British Journal of Haematology · 被引 6)
• Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse (2023 · American Journal of Hematology · 被引 6)